Home » Bristol-Myers Gets FDA Priority Review for Children’s Bipolar Treatment
Bristol-Myers Gets FDA Priority Review for Children’s Bipolar Treatment
Bristol-Myers Squibb Co. and partner Otsuka Pharmaceutical Co. Thursday said the Food and Drug Administration has granted a priority review of the supplemental new drug application for atypical anti-psychotic drug Abilify for the treatment of pediatric patients with bipolar I disorder, manic or mixed episodes with or without psychotic features.
ABCmoney.co.uk
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May